NCT05910827 2026-04-15
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Hummingbird Bioscience
Phase 1/2 Recruiting
Clinical Trials
43 trialsNCT07115043 2026-03-17
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
AstraZeneca
Phase 1/2 Recruiting
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT03786237 2026-02-24
Rigosertib for RDEB-SCC
Salzburger Landeskliniken
Phase 1/2 Completed
NCT07339176 2026-01-14
OP-NEU-101
Onchilles Pharma Inc
Phase 1/2 Not yet recruiting
NCT04260802 2026-01-12
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
Phase 1/2 Terminated
NCT05858229 2025-12-31
Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1.
Rochester Dermatologic Surgery
Phase 1/2 Active not recruiting
NCT04198766 2025-12-18
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Phase 1/2 Active not recruiting
NCT03821272 2025-10-08
A Phase I/II Clinical Trial of PepCan in Head and Neck Cancer Patients
University of Arkansas
Phase 1/2 Completed
NCT04370587 2025-10-08
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
ImmVira Pharma Co. Ltd
Phase 1/2 Recruiting
NCT07010692 2025-09-17
Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment
Bruce Robinson, MD
Phase 1/2 Recruiting
NCT04180215 2025-09-15
A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers
Hookipa Biotech GmbH
Phase 1/2 Completed
NCT04305795 2025-06-19
An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
Rakuten Medical, Inc.
Phase 1/2 Active not recruiting
NCT04442126 2025-05-23
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
Numab Therapeutics AG
Phase 1/2 Terminated
NCT06875791 2025-04-01
TEMOR
Fundacion Clinica Valle del Lili
Phase 1/2 Not yet recruiting
NCT05784012 2025-03-13
RADIAN
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Phase 1/2 Recruiting
NCT03058289 2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2 Completed
NCT03190174 2025-02-17
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
Sarcoma Oncology Research Center, LLC
Phase 1/2 Completed
NCT03387111 2024-08-05
QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03784066 2024-07-03
DUTRELASCO
Universitaire Ziekenhuizen KU Leuven
Phase 1/2 Active not recruiting
NCT01581840 2024-07-01
Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus
Federation Francophone de Cancerologie Digestive
Phase 1/2 Completed
NCT03283605 2024-06-28
Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas
Centre hospitalier de l'Université de Montréal (CHUM)
Phase 1/2 Active not recruiting
NCT03847519 2024-06-04
Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer
Advaxis, Inc.
Phase 1/2 Completed
NCT04410874 2024-03-07
MUSIC-01
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase 1/2 Terminated
NCT00707655 2023-08-03
Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy
Genmab
Phase 1/2 Terminated
NCT05783921 2023-07-28
A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Unknown
NCT03989115 2023-06-26
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
Revolution Medicines, Inc.
Phase 1/2 Completed
NCT01592721 2022-09-21
Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma
The University of Texas Health Science Center at San Antonio
Phase 1/2 Completed
NCT03221400 2022-02-17
PEN-866 in Patients With Advanced Solid Malignancies
Tarveda Therapeutics
Phase 1/2 Unknown
NCT00660218 2021-11-08
A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer
State University of New York - Upstate Medical University
Phase 1/2 Completed
NCT01217060 2021-04-13
Trimodality Management of T1b Esophageal Cancers
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00073398 2020-05-28
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer
Lumos Pharma
Phase 1/2 Completed
NCT03109158 2019-04-29
NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
NanoCarrier Co., Ltd.
Phase 1/2 Completed
NCT00652080 2019-03-05
An Open-Label Safety Study of API 31510 in a Topical Cream for in Situ Cutaneous Squamous Cell Carcinoma (SCCIS)
BPGbio
Phase 1/2 Completed
NCT03817567 2019-01-25
Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma
Sinocelltech Ltd.
Phase 1/2 Unknown
NCT03636685 2018-08-17
Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC
ChineseAMS
Phase 1/2 Unknown
NCT01252628 2018-05-16
Phase 1 and 2 Study of PX-866 and Cetuximab
Seagen Inc.
Phase 1/2 Completed
NCT01195922 2017-12-06
Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT03051906 2017-11-22
DUCRO-HN
Azienda Ospedaliero-Universitaria Careggi
Phase 1/2 Unknown
NCT02298595 2017-11-13
Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
University of Pittsburgh
Phase 1/2 Withdrawn
NCT02059252 2016-04-04
Safety, Tolerability and Performance of SmartMatrix Dermal Replacement Scaffold
Smart Matrix Limited
Phase 1/2 Terminated
NCT01760811 2013-01-04
CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment in Locally Advanced Tongue Cancer ; A NEW PARADIGM OF TREATMENT
Rabin Medical Center
Phase 1/2 Unknown
NCT00139243 2008-06-04
Study of Taxotere, Cisplatin, 5-Fluorouracil, and Leucovorin for Squamous Cell Carcinoma of the Head and Neck
Dana-Farber Cancer Institute
Phase 1/2 Completed